Zydus Cadila is an innovative global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products. Headquartered in the city of Ahmedabad in India, the group has global operations in four continents spread across USA, Europe, Japan, Brazil, South Africa and 25 other emerging markets.
In its mission to create healthier communities globally, Zydus Cadila delivers wide ranging healthcare solutions and value to its customers. With over 10,000 employees worldwide, a world-class research and development centre dedicated to discovery research and eight state-of-the-art manufacturing plants, the group is dedicated to improving people’s lives.
Contact
Address: Carr. Picacho Ajusco , # 154, office 601, 6th floor, Jardines en la Montanya, 14210 Mexico DF. Mexico.
Tel. +52 (55) 26155813
Website: http://zyduscadila.co
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and…
As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian…
Six Indian pharma and biotech firms have joined the global race to develop a vaccine for COVID-19 with India-developed vaccine candidates moving swiftly toward Phase I and II human trials…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
The state of Gujarat proudly stands as India’s main pharmaceutical hub, accounting for over 33 percent of the country’s pharmaceutical turnover and 28 percent of its pharmaceutical exports. Given the…
Juan Luis Fernández Balaguer, general manager of Laboratorios Combix, the Spanish affiliate of Zydus Cadila, shares the milestones achieved by the company since joining the group and its promising future…
As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus…
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years ago. You have had…
See our Cookie Privacy Policy Here
